Reducing Adenoviral Patient-Infected Days
To learn more about the RAPID study, please visit the main website at https://sites.wustl.edu/rapid/
Advancing Knowledge on Adenoviral Conjunctivitis (Pink Eye)
Why is this study needed?
There is no U.S. Food and Drug Administration (FDA) approved treatment for “pink eye”. Standard care recommended by the American Academy of Optometry and American Ophthalmology Academy is with artificial tears to relieve symptoms and to possibly reduce adenovirus in the eye. Another possible treatment is with Betadine 5%, an antiseptic ophthalmic solution used for over 50 years to prepare patient’s eye and surrounding area for eye surgery and to clean minor wounds. Because Betadine 5% kills bacteria and viruses, it may be useful in treating adenoviral conjunctivitis. This study will be among the first to test Betadine 5% for “pink eye”.